Oncolytic gene therapy for canine cancers: Teaching old dog viruses new tricks

Veterinary and Comparative Oncology

Volumn 7, Issue 3, 2009, Pages 153-161

  Arendt, M ^a   Nasir, L ^a   Morgan, I M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Canine cancer; Gene therapy; Oncolytic adenoviruses

Indexed keywords

ANIMAL; ANIMAL DISEASE; CLASSIFICATION; DOG; DOG DISEASE; GENE THERAPY; GENETIC ENGINEERING; METHODOLOGY; NEOPLASM; ONCOLYTIC VIROTHERAPY; REVIEW; VIROLOGY; VIRUS;

ANIMALS; DOG DISEASES; DOGS; GENE THERAPY; GENETIC ENGINEERING; NEOPLASMS; ONCOLYTIC VIROTHERAPY; VIRUSES;

ADENOVIRIDAE; CANINE DISTEMPER VIRUS; CANIS FAMILIARIS; MORBILLIVIRUS;

EID: 68549115521     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2009.00187.x     Document Type: Review

References (71)

1. Bonnett BN, Egenvall A, Olson P and Hedhammar A. Mortality in insured Swedish dogs: Rates and causes of death in various breeds. Veterinary Record 1997; 141: 40-44.
2. Michell AR. Longevity of British breeds of dog and its relationships with sex, size, cardiovascular variables and disease. Veterinary Record 1999; 145: 625-629.
3. Dobson JM, Samuel S, Milstein H, Rogers K and Wood JLN. Canine neoplasia in the UK: Estimates of incidence rates from a population of insured dogs. Journal of Small Animal Practice 2002; 43: 240-246.
4. Proschowsky HF, Rugbjerg H and Ersboll AK. Mortality of purebred and mixed-breed dogs in Denmark. Preventive Veterinary Medicine 2003; 58: 63-74.
5. Hansen K and Khanna C. Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development. European Journal of Cancer 2004; 40: 858-880.
6. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G and Bocchini V. Cancer incidence in pet dogs: Findings of the animal tumor registry of Genoa, Italy. Journal of Veterinary Internal Medicine 2008; 22: 976-984.
7. Paoloni M and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 2008; 8: 147-156.
8. Fielding AK. Measles as a potential oncolytic virus. Reviews in Medical Virology 2005; 15: 135-142.
9. Kenney S and Pagano JS. Viruses as oncolytic agents - a new-age for therapeutic viruses. Journal of the National Cancer Institute 1994; 86: 1185-1186.
10. Ring CJA. Cytolytic viruses as potential anti-cancer agents. Journal of General Virology 2002; 83: 491-502.
11. Kelly E and Russell SJ. History of oncolytic viruses: Genesis to genetic engineering. Molecular Therapy 2007; 15: 651-659.
12. Liu TC, Galanis E and Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nature Clinical Practice Oncology 2007; 4: 101-117.
13. Liu TC and Kirn D. Gene therapy progress and prospects cancer: Oncolytic viruses. Gene Therapy 2008; 15: 877-884.
14. Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O'Neil JD, Roberts MS, Groene WS and Lorence RM. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clinical Cancer Research 2006; 12: 2555-2562.
15. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC and Kirn DH. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncology 2008; 9: 533-542.
16. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK and Lorence RM. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. Journal of Clinical Oncology 2002; 20: 2251-2266.
17. Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O'Neil JD, Roberts MS, Groene WS and Major PP. An optimized clinical regimen for the oncolytic virus PV701. Clinical Cancer Research 2007; 13: 977-985.
18. Everts B and van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Therapy 2005; 12: 141-161.
19. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
20. Shenk T. Adenoviridae: The viruses and their replication. In: Fields Virology, 3rd edn., B. N. Fields, D. M. Knipe and P. M. Howley, eds., New York, Lippencott-Raven, 1996; 2111-2148.
21. Schneider-Schaulies J and Schneider-Schaulies S. Receptor interactions, tropism, and mechanisms involved in morbillivirus induced immunomodulation. Advances in Virus Research 2008; 71: 173-205.
22. Kunzi V, Oberholzer PA, Heinzerling L, Dummer R and Naim HY. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. Journal of Investigative Dermatology 2006; 126: 2525-2532.
23. Harder TC and Osterhaus ADME. Canine distemper virus - a morbillivirus in search of new hosts? Trends in Microbiology 1997; 5: 120-124.
24. Yanagi Y, Takeda M and Ohno S. Measles virus: Cellular receptors, tropism and pathogenesis. Journal of General Virology 2006; 87: 2767-2779.
25. Suter SE, Chein MB, von Messling V, Yip B, Cattaneo R, Vernau W, Madewell BR and London CA. In vitro canine distemper virus infection of canine lymphoid cells: A prelude to oncolytic therapy for lymphoma. Clinical Cancer Research 2005; 11: 1579-1587.
26. Puff C, Krudewig C, Imbschweiler I, Baumgartner W and Alldinger S. Influence of persistent canine distemper virus infection on expression of RECK, matrix-metalloproteinases and their inhibitors in a canine macrophage/monocytic tumour cell line (DH82). The Veterinary Journal 2008. Doi:10.1016/j.tvjl.2008.03.026.
27. Edwards DS, Henley WE, Harding EF, Dobson JM and Wood JLN. Breed incidence of lymphoma in a UK population of insured dogs. Veterinary and Comparative Oncology 2003; 1: 200-206.
28. Heise C and Kirn DH. Replication-selective adenoviruses as oncolytic agents. Journal of Clinical Investigation 2000; 105: 847-851.
29. Guo ZS, Thorne SH and Bartlett DL. Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochemica and Biophysica Acta 2008; 1785: 217-231.
30. Rasmussen UB, Benchaibi M, Meyer V, Schlesinger Y and Schughart K. Novel human gene transfer vectors: Evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Human Gene Therapy 1999; 10: 2587-2599.
31. Ternovoi VV, Le LP, Belousova N, Smith BF, Siegal GP and Curiel DT. Productive replication of human adenovirus type 5 in canine cells. The Journal of Virology 2005; 79: 1308-1311.
32. Freytag SO, Barton KN, Brown SL, Narra V, Zhang Y, Tyson D, Nall C, Lu M, Ajlouni M, Movsas B and Kim JH. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Molecular Therapy 2007; 15: 1600-1606.
33. Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang MH, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP and Curiel DT. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Molecular Therapy 2003; 7: 163-173.
34. Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K and Wildner O. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. Journal of Virology 2006; 80: 3549-3558.
35. Adam SJ, Rund LA, Kuzmuk KN, Zachary JF, Schook LB and Counter CM. Genetic induction of tumorigenesis in Swine. Oncogene 2007; 26: 1038-1045.
36. Wang XH, Su CQ, Cao H, Li K, Chen J, Jiang LX, Zhang Q, Wu XB, Jia XY, Liu YJ, Wang WG, Liu XY, Wu MC and Qian QJ. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Molecular Cancer Therapeutics 2008; 7: 1598-1603.
37. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. Journal of the National Cancer Institute 2006; 98: 298-300.
38. Barton KN, Paielli D, Zhang Y, Koul S, Brown SL, Lu M, Seely J, Kim JH and Freytag S.O. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Molecular Therapy 2006; 13: 347-356.
39. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A and Kim JH. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Molecular Therapy 2007; 15: 1016-1023.
40. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D and Hwang TH. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Molecular Therapy 2006; 14: 361-370.
41. Cattaneo R, Miest T, Shashkova EV and Barry MA. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nature Reviews Microbiology 2008; 6: 529-540.
42. Kirn DH and Thorne SH. Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer. Nature Reviews Cancer 2009; 9: 64-71.
43. Yuti C, Layward L and Lemoine N. Fighting cancer with oncolytic viruses. British Medical Journal 2006; 332: 170-172.
44. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA and Wolchok JD. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006; 24: 4582-4585.
45. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV and Woo SLC. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Therapy 2003; 10: 1241-1247.
46. Uchino J, Takayama K, Harada A, Kawakami Y, Inoue H, Curiel DT and Nakanishi Y. Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. Cancer Gene Therapy 2005; 12: 737-748.
47. Zhang LQ, Adams JY, Billick E, Ilagan R, Iyer M, Le K, Smallwood A, Gambhir SS, Carey M and Wu LL. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Molecular Therapy 2002; 5: 223-232.
48. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM and Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism 2003; 80: 148-158.
49. Kremer EJ, Boutin S, Chillon M and Danos O. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. The Journal of Virology 2000; 74: 505-512.
50. Kremer EJ. CAR chasing: Canine adenovirus vectors - all bite and no bark? Journal of Gene Medicine 2004; 6: S139-S151.
51. Decaro N, Martella V and Buonavoglia C. Canine adenoviruses and herpesvirus. Veterinary Clinics of North America-Small Animal Practice 2008; 38: 799.
52. Buonavoglia C and Martella V. Canine respiratory viruses. Veterinary Research 2007; 38: 355-373.
53. Chun R and de Lorimier LP. Update on the biology and management of canine osteosarcoma. Veterinary Clinics of North America-Small Animal Practice 2003; 33: 491.
54. Le LP, Rivera AA, Glasgow JN, Ternovoi VV, Wu H, Wang M, Smith BF, Siegal GP and Curiel DT. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Therapy 2006; 13: 389-399.
55. Smith BF, Curiel DT, Ternovoi VV, Borovjagin AV, Baker HJ, Cox N and Siegal GP. Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer Biotherapy and Radiopharmaceuticals 2006; 21: 601-606.
56. Iyer M, Wu L, Carey M, Wang Y, Smallwood A and Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proceedings of the National Academy of Sciences USA 2001; 98: 14595-14600.
57. Russell WC. Update an adenovirus and its vectors. Journal of General Virology 2000; 81: 2573-2604.
58. Muruve DA. The innate immune response to adenovirus vectors. Human Gene Therapy 2004; 15: 1157-1166.
59. Hoption Cann SA, van Netten JP and van Netten C. Dr William Coley and tumour regression: A place in history or in the future. Postgraduate Medical Journal 2003; 79: 672-680.
60. Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Hallden G, Mautner V, Shen Y and Seymour LW. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus 1. Human Gene Therapy 2008; 19: 873-886.
61. Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J and Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway 1. Molecular Therapy 2007; 15: 1607-1615.
62. Duerner LJ, Schwantes A, Schneider IC, Cichutek K and Buchholz CJ. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue. Gene Therapy 2008; 15: 1500-1510.
63. Fueyo J, Gomez-Manzano C, Alemany R, Lee PSN, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WKA and Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
64. Guse K, Ranki T, Ala-Opas M, Bono P, Sarkioja M, Rajecki M, Kanerva A, Hakkarainen T and Hemminki A. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Molecular Cancer Therapeutics 2007; 6: 2728-2736.
65. Kanerva A, Lavilla-Alonso S, Raki M, Kangasniemi L, Bauerschmitz GJ, Takayama K, Ristimaki A, Desmond RA and Hemmenki A. Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses. PLoS ONE 2008; 3: E2978.
66. Kim M, Chung YH and Johnston RN. Reovirus and tumor oncolysis. Journal of Microbiology 2007; 45: 187-192.
67. Kinoh H, Inoue M, Washizawa K, Yamamoto T, Fujikawa S, Tokusumi Y, Iida A, Nagai Y and Hasegawa M. Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Therapy 2004; 11: 1137-1145.
68. Noser JA, Mael AA, Sakuma R, Ohmine S, Marcato P, Lee PWK and Ikeda Y. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: Implication for the defective interferon response in cancer cells. Molecular Therapy 2007; 15: 1531-1536.
69. Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad, CA, Aldape KD, Gomez-Manzano C and Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Therapy 2009; 16: 256-265.
70. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ and Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Research 2006; 66: 7694-7700.
71. Zhang W, Cai R, Luo JJ, Wang YX, Cui Q, Wei XB, Zhang HF and Qian C. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biology and Therapy 2007; 6: 1726-1732.